-+ 0.00%
-+ 0.00%
-+ 0.00%

Sumitomo Pharma rejects Gotham City Research report claims on AMCHEPRY®

PUBT·08/11/2026 23:38:48
Listen to the news
Sumitomo Pharma rejects Gotham City Research report claims on AMCHEPRY®
  • Sumitomo Pharma rejected Gotham City Research’s Aug. 7 report as unilateral assertions, noting the publisher disclosed short positions.
  • AMCHEPRY materials for regulatory review were confirmed reliable; the therapy received conditional, time-limited clearance following regulator assessment.
  • A Phase 4 post-marketing study is ongoing to build efficacy and safety evidence, targeting full approval as early as possible.
  • The company flagged a separate Aug. 3 GCR report on financial reporting, signaling potential legal action over inaccurate or misleading claims.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.